[Synthesis of pyrrolidine derivatives with pharmacological activity. X. Synthesis of 1,1-diethyl- and 1,1-(epimeric)-ethylmethyl-2-methyl-4-diphenyl-methylenepyrrolidinium iodides as potential anticholinergic agents (author's transl)]. 1980

N Ozawa, and F Hamaguchi, and T Nagasaka, and H Matsuda, and Y Kosugi, and S Ohki

UI MeSH Term Description Entries
D008968 Molecular Conformation The characteristic three-dimensional shape of a molecule. Molecular Configuration,3D Molecular Structure,Configuration, Molecular,Molecular Structure, Three Dimensional,Three Dimensional Molecular Structure,3D Molecular Structures,Configurations, Molecular,Conformation, Molecular,Conformations, Molecular,Molecular Configurations,Molecular Conformations,Molecular Structure, 3D,Molecular Structures, 3D,Structure, 3D Molecular,Structures, 3D Molecular
D010276 Parasympatholytics Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. Antispasmodic,Antispasmodic Agent,Antispasmodic Drug,Antispasmodics,Parasympathetic-Blocking Agent,Parasympathetic-Blocking Agents,Parasympatholytic,Parasympatholytic Agent,Parasympatholytic Drug,Spasmolytic,Spasmolytics,Antispasmodic Agents,Antispasmodic Drugs,Antispasmodic Effect,Antispasmodic Effects,Parasympatholytic Agents,Parasympatholytic Drugs,Parasympatholytic Effect,Parasympatholytic Effects,Agent, Antispasmodic,Agent, Parasympathetic-Blocking,Agent, Parasympatholytic,Agents, Antispasmodic,Agents, Parasympathetic-Blocking,Agents, Parasympatholytic,Drug, Antispasmodic,Drug, Parasympatholytic,Drugs, Antispasmodic,Drugs, Parasympatholytic,Effect, Antispasmodic,Effect, Parasympatholytic,Effects, Antispasmodic,Effects, Parasympatholytic,Parasympathetic Blocking Agent,Parasympathetic Blocking Agents
D011759 Pyrrolidines Compounds also known as tetrahydropyridines with general molecular formula (CH2)4NH. Tetrahydropyridine,Tetrahydropyridines
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

N Ozawa, and F Hamaguchi, and T Nagasaka, and H Matsuda, and Y Kosugi, and S Ohki
January 1978, Acta poloniae pharmaceutica,
N Ozawa, and F Hamaguchi, and T Nagasaka, and H Matsuda, and Y Kosugi, and S Ohki
May 1969, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,
N Ozawa, and F Hamaguchi, and T Nagasaka, and H Matsuda, and Y Kosugi, and S Ohki
October 1990, Acta chemica Scandinavica (Copenhagen, Denmark : 1989),
N Ozawa, and F Hamaguchi, and T Nagasaka, and H Matsuda, and Y Kosugi, and S Ohki
March 2018, Bioorganic & medicinal chemistry letters,
N Ozawa, and F Hamaguchi, and T Nagasaka, and H Matsuda, and Y Kosugi, and S Ohki
January 1994, Acta poloniae pharmaceutica,
N Ozawa, and F Hamaguchi, and T Nagasaka, and H Matsuda, and Y Kosugi, and S Ohki
March 1967, Japanese journal of pharmacology,
N Ozawa, and F Hamaguchi, and T Nagasaka, and H Matsuda, and Y Kosugi, and S Ohki
November 1973, Archiv der Pharmazie,
N Ozawa, and F Hamaguchi, and T Nagasaka, and H Matsuda, and Y Kosugi, and S Ohki
July 1981, Annales pharmaceutiques francaises,
N Ozawa, and F Hamaguchi, and T Nagasaka, and H Matsuda, and Y Kosugi, and S Ohki
January 1999, Acta poloniae pharmaceutica,
Copied contents to your clipboard!